secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001193125-23-248461
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi appoints Dave Lennon as President and CEO; base salary $640K, option for 490K shares
--------------------------------------------------------------------------------

- David J. Lennon appointed President and CEO, effective Oct 2, 2023; Scott Giacobello returns to CFO role.
- Compensation: $640,000 base salary, up to 60% annual bonus, $240,000 sign-on (cash + RSUs), option for 490,000 shares.
- Board increased from 8 to 9; Lennon appointed as Class II director. Company adopted 2023 Inducement Plan reserving 600,000 shares.
- Press release highlights Lennon’s Novartis background and FYARRO pipeline expansion into endometrial, neuroendocrine cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/d561858d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-248461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer